Search research articles
Contact Us
Filters
Showing results (1-10 of 68) with videos related to
Page
of 7
Sort By:
Trends in Cancer
|
September 1, 2023
Interferon signaling restrains renal cell carcinoma heterogeneity
Peter Holicek, Jitka Fucikova, Lorenzo Galluzzi
Cell Research
|
August 1, 2020
Calreticulin and cancer
Jitka Fucikova, Radek Spisek, Guido Kroemer, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Iva Truxova, David Cibula, Radek Spisek, et al.
Oncoimmunology
|
February 1, 2020
Calreticulin arms NK cells against leukemia
Jitka Fucikova, Justin P Kline, Lorenzo Galluzzi, et al.
Frontiers in Immunology
|
November 19, 2019
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Jitka Fucikova, Lenka Palova-Jelinkova, Jirina Bartunkova, et al.
Oncoimmunology
|
October 25, 2019
Apoptotic caspases cut down the immunogenicity of radiation
Aitziber Buqué, Maria Esperanza Rodriguez-Ruiz, Jitka Fucikova, et al.
Oncoimmunology
|
May 13, 2015
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Irena Adkins, Jitka Fucikova, Abhishek D Garg, et al.
Cancer Immunology, Immunotherapy : CII
|
August 28, 2012
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Ashley J Knights, Jitka Fucikova, Anupama Pasam, et al.
Immunology Letters
|
April 15, 2014
Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs
Iva Truxova, Katerina Pokorna, Kamila Kloudova, et al.
Immunology Letters
|
November 28, 2017
Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer
Jitka Fucikova, Lenka Kasikova, Iva Truxova, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 68) with videos related to
Sort By:
Page
of 7
Trends in Cancer
|
September 1, 2023
Interferon signaling restrains renal cell carcinoma heterogeneity
Peter Holicek, Jitka Fucikova, Lorenzo Galluzzi
Cell Research
|
August 1, 2020
Calreticulin and cancer
Jitka Fucikova, Radek Spisek, Guido Kroemer, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Iva Truxova, David Cibula, Radek Spisek, et al.
Oncoimmunology
|
February 1, 2020
Calreticulin arms NK cells against leukemia
Jitka Fucikova, Justin P Kline, Lorenzo Galluzzi, et al.
Frontiers in Immunology
|
November 19, 2019
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Jitka Fucikova, Lenka Palova-Jelinkova, Jirina Bartunkova, et al.
Oncoimmunology
|
October 25, 2019
Apoptotic caspases cut down the immunogenicity of radiation
Aitziber Buqué, Maria Esperanza Rodriguez-Ruiz, Jitka Fucikova, et al.
Oncoimmunology
|
May 13, 2015
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
Irena Adkins, Jitka Fucikova, Abhishek D Garg, et al.
Cancer Immunology, Immunotherapy : CII
|
August 28, 2012
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Ashley J Knights, Jitka Fucikova, Anupama Pasam, et al.
Immunology Letters
|
April 15, 2014
Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs
Iva Truxova, Katerina Pokorna, Kamila Kloudova, et al.
Immunology Letters
|
November 28, 2017
Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer
Jitka Fucikova, Lenka Kasikova, Iva Truxova, et al.
Page
of 7